Pinnacle Financial Group, Inc.’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Pinnacle Financial Group, Inc.'s PLX Position: Q3 2026 in Review
Pinnacle Financial Group, Inc. opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 350 shares worth $966. The stake represents ﹤0.01% of the portfolio and ranks #2087 among its holdings.
106 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Pinnacle Financial Group, Inc. held 350 shares of Protalix BioTherapeutics worth $966 as of Q3 2026.
- Protalix BioTherapeutics was a new Pinnacle Financial Group, Inc. position in Q3 2026.
- Protalix BioTherapeutics made up ﹤0.01% of Pinnacle Financial Group, Inc.'s portfolio in Q3 2026, its #2087 holding.
- 106 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Pinnacle Financial Group, Inc.'s 13F filing for Q3 2026, filed 16 Nov 2026.